X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (277) 277
clarithromycin (224) 224
helicobacter pylori (158) 158
anti-bacterial agents - therapeutic use (150) 150
female (146) 146
helicobacter infections - drug therapy (145) 145
male (142) 142
adult (118) 118
clarithromycin - therapeutic use (116) 116
index medicus (112) 112
middle aged (108) 108
gastroenterology & hepatology (100) 100
drug therapy, combination (95) 95
infection (95) 95
treatment outcome (95) 95
aged (81) 81
helicobacter pylori - drug effects (76) 76
pharmacology & pharmacy (70) 70
antibiotics (68) 68
amoxicillin (66) 66
anti-bacterial agents - administration & dosage (66) 66
anti-bacterial agents - economics (64) 64
cost-benefit analysis (56) 56
clarithromycin - administration & dosage (55) 55
clarithromycin - economics (55) 55
eradication (55) 55
amoxicillin - therapeutic use (54) 54
helicobacter infections - microbiology (50) 50
management (49) 49
medicine, general & internal (48) 48
metronidazole (48) 48
adolescent (46) 46
therapy (44) 44
helicobacter infections - economics (42) 42
anti-ulcer agents - therapeutic use (41) 41
helicobacter infections - diagnosis (41) 41
helicobacter pylori - isolation & purification (41) 41
amoxicillin - administration & dosage (40) 40
helicobacter infections (39) 39
triple therapy (39) 39
anti-bacterial agents - pharmacology (38) 38
efficacy (38) 38
microbiology (38) 38
omeprazole - therapeutic use (38) 38
prevalence (38) 38
aged, 80 and over (37) 37
drug therapy (37) 37
infections (37) 37
omeprazole (37) 37
risk factors (36) 36
antibiotic-resistance (35) 35
research (35) 35
prospective studies (34) 34
resistance (34) 34
azithromycin (33) 33
health aspects (33) 33
infectious diseases (33) 33
drug administration schedule (31) 31
care and treatment (30) 30
clarithromycin - pharmacology (29) 29
double-blind method (29) 29
proton pump inhibitors (29) 29
anti-bacterial agents - adverse effects (28) 28
anti-ulcer agents - economics (28) 28
clarithromycin resistance (28) 28
erythromycin (28) 28
metaanalysis (27) 27
microbial sensitivity tests (27) 27
diagnosis (26) 26
drug resistance (26) 26
drug resistance, bacterial (26) 26
metronidazole - therapeutic use (26) 26
antimicrobial resistance (25) 25
breath tests (25) 25
community-acquired infections - drug therapy (25) 25
helicobacter infections - complications (25) 25
omeprazole - administration & dosage (25) 25
amoxicillin - economics (24) 24
anti-ulcer agents - administration & dosage (24) 24
community-acquired pneumonia (24) 24
duodenal-ulcer (24) 24
pneumonia (24) 24
clarithromycin - adverse effects (23) 23
duodenal ulcer - drug therapy (23) 23
medicine (23) 23
lansoprazole (22) 22
omeprazole - economics (22) 22
retrospective studies (22) 22
animals (21) 21
helicobacter infections - epidemiology (21) 21
helicobacter pylori - genetics (21) 21
peptic ulcer - drug therapy (21) 21
proton pump inhibitor (21) 21
proton pump inhibitors - therapeutic use (21) 21
epidemiology (20) 20
recurrence (20) 20
united-states (20) 20
adults (19) 19
anti-infective agents - therapeutic use (19) 19
biopsy (19) 19
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (355) 355
Russian (6) 6
Spanish (5) 5
French (4) 4
Korean (4) 4
Japanese (2) 2
Dutch (1) 1
German (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Infection and Drug Resistance, ISSN 1178-6973, 09/2019, Volume 12, pp. 3051 - 3061
Aims and objectives: Helicobacter pylori has been classified as high priority pathogen by the WHO in 2017. The emergence of antibiotic-resistant strains is one... 
Levofloxacin | Clarithromycin | Mixed infection | Laboratories | rRNA | Genes | rRNA 23S | Antimicrobial agents | Infections | RNA polymerase | Drug resistance | Epidemiology | Patients | Medicine | Immunology | Antibiotics | Biopsy | Antibiotic resistance | Endoscopy | Mutation | Metronidazole | Failure | metronidazole | clarithromycin | Helicobacter pylori | antibiotic resistance | levofloxacin | point mutation
Journal Article
Acta Medica Iranica, ISSN 0044-6025, 07/2019, Volume 57, Issue 4
Helicobacter pylori (HBP) is reported as one of the main causes of peptic ulcer disease (PUD) and gastric cancer in the world. The challenge for finding an... 
Clarithromycin | Helicobacter pylori | Amoxicillin | Proton pump inhibitors
Journal Article
BMC Infectious Diseases, ISSN 1471-2334, 06/2019, Volume 19, Issue 1
The effectiveness of Helicobacter pylori first-line treatment has decreased drastically with the rise of strains resistant to clarithromycin. Therapy failure... 
Polymerase chain reaction | Clarithromycin | Usage | Helicobacter infections | Genetic aspects | Drug therapy | Risk factors
Journal Article
Gut, ISSN 0017-5749, 06/2019, Volume 68, Issue Suppl 2, p. A151
Introduction Helicobacter pylori (H. pylori) infection is the primary cause of peptic ulcer disease and is globally prevalent. Although eradication therapy is... 
Journal Article
Basic & Clinical Pharmacology & Toxicology, ISSN 1742-7835, 05/2019, Volume 124, Issue 5, pp. 582 - 590
Register‐based administrative data comprise the backbone of pharmacoepidemiological research. However, information from these registers lacks biochemical... 
CLARITHROMYCIN | REGISTERS | PRESCRIPTION | RISK | PHARMACOLOGY & PHARMACY | TOXICOLOGY | HEALTH | EPIDEMIOLOGY | DANISH | Chronic kidney failure | Medicine, Experimental | Medical research | Creatinine | Kidneys | Laboratories | Pharmacology | Registers | Kidney diseases | Diagnosis | Discharge
Journal Article
Helicobacter, ISSN 1083-4389, 04/2019, Volume 24, Issue 2, pp. e12566 - n/a
Journal Article
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 04/2019, Volume 34, Issue 4, pp. 700 - 706
Background and Aim The Helicobacter pylori eradication rate using conventional triple therapy has decreased due to clarithromycin (CAM) resistance in... 
dual priming oligonucleotide‐based polymerase chain reaction | cost‐effectiveness | Helicobacter pylori | clarithromycin resistance | eradication | dual priming oligonucleotide-based polymerase chain reaction | cost-effectiveness | MANAGEMENT | METAANALYSIS | GUIDELINES | ANTIBIOTIC-RESISTANCE | PREVALENCE | ANTIMICROBIAL RESISTANCE | GASTRIC-CANCER | TRIPLE THERAPY | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | PCR | Humans | Middle Aged | Helicobacter pylori - genetics | Precision Medicine - economics | Helicobacter pylori - drug effects | Male | Gastritis - economics | Helicobacter Infections | Polymerase Chain Reaction - methods | Young Adult | RNA, Ribosomal, 23S - genetics | Aged, 80 and over | Gastritis - microbiology | Adult | Female | Clarithromycin - economics | Drug Resistance, Bacterial - genetics | Anti-Bacterial Agents - economics | Gastritis - diagnosis | Gastritis - drug therapy | Drug Therapy, Combination - economics | Point Mutation | Asian Continental Ancestry Group | Cost-Benefit Analysis | Aged | Anti-Bacterial Agents - pharmacology | Clarithromycin - pharmacology | Precision Medicine - methods | Drug resistance in microorganisms | Enzymes | Clarithromycin | Gene mutations | Ribosomal RNA | Genetic research | Hydrolases | Genetic aspects | Polymerase chain reaction | Pathogens | rRNA | rRNA 23S | Point mutation | Urease | Mutation | Patients
Journal Article
Journal Article
Medicine, ISSN 0025-7974, 02/2019, Volume 98, Issue 6, p. e14408
Journal Article